S&P 500   4,021.06 (+1.25%)
DOW   32,669.79 (+0.85%)
QQQ   311.88 (+1.55%)
AAPL   160.20 (+1.62%)
MSFT   279.31 (+1.48%)
META   205.12 (+2.21%)
GOOGL   101.37 (+0.34%)
AMZN   100.03 (+2.87%)
TSLA   192.00 (+1.49%)
NVDA   268.86 (+1.80%)
NIO   9.93 (+7.93%)
BABA   100.96 (+2.60%)
AMD   95.82 (+1.33%)
T   19.01 (+1.55%)
F   11.98 (+3.28%)
MU   63.43 (+7.00%)
CGC   1.83 (+1.10%)
GE   94.14 (+1.07%)
DIS   96.57 (+1.85%)
AMC   4.96 (-3.69%)
PFE   40.13 (+0.35%)
PYPL   73.95 (+1.72%)
NFLX   330.67 (+2.21%)
S&P 500   4,021.06 (+1.25%)
DOW   32,669.79 (+0.85%)
QQQ   311.88 (+1.55%)
AAPL   160.20 (+1.62%)
MSFT   279.31 (+1.48%)
META   205.12 (+2.21%)
GOOGL   101.37 (+0.34%)
AMZN   100.03 (+2.87%)
TSLA   192.00 (+1.49%)
NVDA   268.86 (+1.80%)
NIO   9.93 (+7.93%)
BABA   100.96 (+2.60%)
AMD   95.82 (+1.33%)
T   19.01 (+1.55%)
F   11.98 (+3.28%)
MU   63.43 (+7.00%)
CGC   1.83 (+1.10%)
GE   94.14 (+1.07%)
DIS   96.57 (+1.85%)
AMC   4.96 (-3.69%)
PFE   40.13 (+0.35%)
PYPL   73.95 (+1.72%)
NFLX   330.67 (+2.21%)
S&P 500   4,021.06 (+1.25%)
DOW   32,669.79 (+0.85%)
QQQ   311.88 (+1.55%)
AAPL   160.20 (+1.62%)
MSFT   279.31 (+1.48%)
META   205.12 (+2.21%)
GOOGL   101.37 (+0.34%)
AMZN   100.03 (+2.87%)
TSLA   192.00 (+1.49%)
NVDA   268.86 (+1.80%)
NIO   9.93 (+7.93%)
BABA   100.96 (+2.60%)
AMD   95.82 (+1.33%)
T   19.01 (+1.55%)
F   11.98 (+3.28%)
MU   63.43 (+7.00%)
CGC   1.83 (+1.10%)
GE   94.14 (+1.07%)
DIS   96.57 (+1.85%)
AMC   4.96 (-3.69%)
PFE   40.13 (+0.35%)
PYPL   73.95 (+1.72%)
NFLX   330.67 (+2.21%)
S&P 500   4,021.06 (+1.25%)
DOW   32,669.79 (+0.85%)
QQQ   311.88 (+1.55%)
AAPL   160.20 (+1.62%)
MSFT   279.31 (+1.48%)
META   205.12 (+2.21%)
GOOGL   101.37 (+0.34%)
AMZN   100.03 (+2.87%)
TSLA   192.00 (+1.49%)
NVDA   268.86 (+1.80%)
NIO   9.93 (+7.93%)
BABA   100.96 (+2.60%)
AMD   95.82 (+1.33%)
T   19.01 (+1.55%)
F   11.98 (+3.28%)
MU   63.43 (+7.00%)
CGC   1.83 (+1.10%)
GE   94.14 (+1.07%)
DIS   96.57 (+1.85%)
AMC   4.96 (-3.69%)
PFE   40.13 (+0.35%)
PYPL   73.95 (+1.72%)
NFLX   330.67 (+2.21%)
NASDAQ:INO

Inovio Pharmaceuticals - INO Stock Forecast, Price & News

$0.87
+0.01 (+0.72%)
(As of 03/29/2023 02:46 PM ET)
Add
Compare
Today's Range
$0.84
$0.89
50-Day Range
$0.86
$1.91
52-Week Range
$0.79
$4.00
Volume
3.98 million shs
Average Volume
4.35 million shs
Market Capitalization
$225.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.33

Inovio Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
1.80 Rating Score
Upside/​Downside
168.7% Upside
$2.33 Price Target
Short Interest
Bearish
15.19% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.77
Upright™ Environmental Score
News Sentiment
0.83mentions of Inovio Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$21,643 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.52) to ($0.37) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

342nd out of 999 stocks

Surgical & Medical Instruments Industry

34th out of 103 stocks


INO stock logo

About Inovio Pharmaceuticals (NASDAQ:INO) Stock

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Receive INO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inovio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

INO Stock News Headlines

Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
Why Inovio (INO) Shares Are Moving After-Hours
See More Headlines
Receive INO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inovio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

INO Company Calendar

Last Earnings
3/01/2023
Today
3/29/2023
Next Earnings (Estimated)
5/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INO
Employees
317
Year Founded
1979

Price Target and Rating

Average Stock Price Forecast
$2.33
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+171.0%
Consensus Rating
Hold
Rating Score (0-4)
1.80
Research Coverage
5 Analysts

Profitability

Net Income
$-279,820,000.00
Net Margins
-2,726.74%
Pretax Margin
-2,705.64%

Debt

Sales & Book Value

Annual Sales
$10.26 million
Book Value
$0.89 per share

Miscellaneous

Free Float
251,548,000
Market Cap
$224.00 million
Optionable
Optionable
Beta
1.09

Social Links


Key Executives

  • Jacqueline E. Shea
    President, Chief Executive Officer & Director
  • Peter D. KiesPeter D. Kies
    Chief Financial Officer
  • Stephen Kemmerrer
    Senior Vice President-Engineering Development
  • Laurent M. HumeauLaurent M. Humeau
    Chief Scientific Officer
  • Jeffrey Skolnik
    Senior Vice President-Clinical Development













INO Stock - Frequently Asked Questions

Should I buy or sell Inovio Pharmaceuticals stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last twelve months. There are currently 1 sell rating and 4 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" INO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INO, but not buy additional shares or sell existing shares.
View INO analyst ratings
or view top-rated stocks.

What is Inovio Pharmaceuticals' stock price forecast for 2023?

5 Wall Street analysts have issued 1-year target prices for Inovio Pharmaceuticals' stock. Their INO share price forecasts range from $2.00 to $3.00. On average, they anticipate the company's stock price to reach $2.33 in the next twelve months. This suggests a possible upside of 169.0% from the stock's current price.
View analysts price targets for INO
or view top-rated stocks among Wall Street analysts.

How have INO shares performed in 2023?

Inovio Pharmaceuticals' stock was trading at $1.56 at the start of the year. Since then, INO stock has decreased by 44.4% and is now trading at $0.8673.
View the best growth stocks for 2023 here
.

When is Inovio Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our INO earnings forecast
.

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced its earnings results on Wednesday, March, 1st. The biopharmaceutical company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by $0.06. The biopharmaceutical company had revenue of $0.13 million for the quarter, compared to analyst estimates of $0.46 million. Inovio Pharmaceuticals had a negative trailing twelve-month return on equity of 98.03% and a negative net margin of 2,726.74%. During the same period last year, the firm posted ($0.50) earnings per share.

When did Inovio Pharmaceuticals' stock split?

Shares of Inovio Pharmaceuticals reverse split on the morning of Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2014. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

What is J. Joseph Kim's approval rating as Inovio Pharmaceuticals' CEO?

12 employees have rated Inovio Pharmaceuticals Chief Executive Officer J. Joseph Kim on Glassdoor.com. J. Joseph Kim has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Inovio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Novavax (NVAX), Moderna (MRNA), Gilead Sciences (GILD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE), Micron Technology (MU), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).

What is Inovio Pharmaceuticals' stock symbol?

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

Who are Inovio Pharmaceuticals' major shareholders?

Inovio Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (1.96%), Millennium Management LLC (1.73%), Renaissance Technologies LLC (1.03%), Bank of America Corp DE (0.99%), Charles Schwab Investment Management Inc. (0.75%) and Barclays PLC (0.54%). Insiders that own company stock include David B Weiner, David B Weiner, Jacqueline Elizabeth Shea, Jong Joseph Kim, Laurent Humeau, Lota S Zoth, Peter Kies and Simon X Benito.
View institutional ownership trends
.

How do I buy shares of Inovio Pharmaceuticals?

Shares of INO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inovio Pharmaceuticals' stock price today?

One share of INO stock can currently be purchased for approximately $0.87.

How much money does Inovio Pharmaceuticals make?

Inovio Pharmaceuticals (NASDAQ:INO) has a market capitalization of $225.61 million and generates $10.26 million in revenue each year. The biopharmaceutical company earns $-279,820,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis.

How many employees does Inovio Pharmaceuticals have?

The company employs 317 workers across the globe.

How can I contact Inovio Pharmaceuticals?

Inovio Pharmaceuticals' mailing address is 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462. The official website for the company is www.inovio.com. The biopharmaceutical company can be reached via phone at (267) 440-4200, via email at investor.relations@inovio.com, or via fax at 267-440-4242.

This page (NASDAQ:INO) was last updated on 3/29/2023 by MarketBeat.com Staff